Zagazig University, Faculty of Pharmacy, Pharmaceutical Analytical Chemistry Department, Zagazig 44519, Egypt.
Egyptian Russian University, Faculty of Pharmacy, Pharmaceutical Chemistry Department, Badr City, Cairo 11829, Egypt.
J AOAC Int. 2023 Jul 17;106(4):1056-1069. doi: 10.1093/jaoacint/qsad029.
The bupivacaine (BVC)/meloxicam (MLX) combination is the first extended-release dual-acting local anesthetic (DALA) that provides 72 h of postoperative pain relief. It reduces opioid use after surgery and manages pain better than BVC alone over 72 h, and overcomes surgical site inflammation with a new synergistic mode of action that combines BVC with a low dosage of MLX.
In today's pharmaceutical research, we take great care to only use non-toxic solvents that pose no threat to either humans or the environment. This work determines BVC and MLX simultaneously, utilizing water and 0.1 M HCl in water as solvents. Moreover, the eco-friendliness of the specified solvents and the whole method development steps was evaluated based on how user-friendly they were using four standard methodologies.
The developed spectrophotometric methods depended on either zero-order, derivative, or ratio spectra that only required simple mathematical handling. The current techniques include dual wavelength (DW), Fourier self-deconvolution (FSD), first derivative (D1), ratio difference (RD), and first ratio derivative (DD1).
Linearity was confirmed over a concentration range of 50-700 μg/mL for BVC and 1-10 μg/mL for MLX. For BVC and MLX, the LOQs were 26.85-41.33 μg/mL and 0.21-0.95 μg/mL, while the LODs were 8.86-13.64 μg/mL and 0.06-0.31 μg/mL, respectively. For the full validation of the proposed methods, ICH (international conference on harmonization) criteria were followed.
Current methods have the advantage of sticking to the basis of zero-order, derivative, or ratio spectra and needing just the barest minimum of data processing: no complex software, lengthy stages, or transformations are needed.
No spectrophotometric methods have been published for the simultaneous analysis of BVC and MLX. As a result, the newly developed spectrophotometric approaches have great relevance and originality in the field of pharmaceutical analysis.
布比卡因(BVC)/美洛昔康(MLX)联合是首个提供 72 小时术后镇痛的长效双作用局部麻醉剂(DALA)。它减少了手术后的阿片类药物使用,并在 72 小时内比单独使用 BVC 更好地管理疼痛,并且通过一种新的协同作用模式克服了手术部位炎症,该模式将 BVC 与低剂量 MLX 结合使用。
在当今的药物研究中,我们非常注意仅使用对人类或环境没有威胁的无毒溶剂。这项工作使用水和 0.1 M HCl 作为溶剂,同时对 BVC 和 MLX 进行定量分析。此外,还根据四种标准方法的易用性,对指定溶剂和整个方法开发步骤的生态友好性进行了评估。
所开发的分光光度法要么依赖于零阶、导数或比值光谱,仅需要简单的数学处理。目前的技术包括双波长(DW)、傅里叶自解卷积(FSD)、一阶导数(D1)、比值差(RD)和一阶比值导数(DD1)。
BVC 的浓度范围为 50-700μg/mL,MLX 的浓度范围为 1-10μg/mL,在此范围内均获得了线性关系。对于 BVC 和 MLX,LOQ 分别为 26.85-41.33μg/mL 和 0.21-0.95μg/mL,而 LOD 分别为 8.86-13.64μg/mL 和 0.06-0.31μg/mL。为了充分验证所提出方法的有效性,遵循了 ICH(国际协调会议)标准。
目前的方法具有以下优点:坚持使用零阶、导数或比值光谱的基础,只需要最少量的数据处理:不需要复杂的软件、冗长的阶段或变换。
尚未有文献报道同时分析 BVC 和 MLX 的分光光度法。因此,新开发的分光光度法在药物分析领域具有重要的相关性和创新性。